Literature DB >> 16569891

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

George Sakoulas1, Jeff Alder, Claudie Thauvin-Eliopoulos, Robert C Moellering, George M Eliopoulos.   

Abstract

We studied vancomycin and daptomycin susceptibility in methicillin-resistant Staphylococcus aureus from patients exposed to vancomycin, glycopeptide-intermediate S. aureus, and S. aureus passaged in vancomycin-containing medium. A correlation between vancomycin and daptomycin heteroresistance was noted in some strains, suggesting that exposure of S. aureus to vancomycin may affect susceptibility to daptomycin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569891      PMCID： PMC1426932          DOI： 10.1128/AAC.50.4.1581-1585.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus.

Authors:  R Geisel; F J Schmitz; A C Fluit; H Labischinski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-10       Impact factor: 3.267

2.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy.

Authors:  K Sieradzki; T Leski; J Dick; L Borio; A Tomasz
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  George Sakoulas; George M Eliopoulos; Jeff Alder; Claudie Thauvin Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Authors:  George Sakoulas; George M Eliopoulos; Robert C Moellering; Richard P Novick; Lata Venkataraman; Christine Wennersten; Paola C DeGirolami; Mitchell J Schwaber; Howard S Gold
Journal:  J Infect Dis       Date:  2003-03-06       Impact factor: 5.226

6.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

Review 7.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance.

Authors:  K Hiramatsu
Journal:  Lancet Infect Dis       Date:  2001-10       Impact factor: 25.071

8.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

9.  Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

Authors:  Scott K Fridkin; Jeff Hageman; Linda K McDougal; Jasmine Mohammed; William R Jarvis; Trish M Perl; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

10.  Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

Authors:  Venkata G Meka; Satish K Pillai; George Sakoulas; Christine Wennersten; Lata Venkataraman; Paola C DeGirolami; George M Eliopoulos; Robert C Moellering; Howard S Gold
Journal:  J Infect Dis       Date:  2004-06-09       Impact factor: 5.226
View more
  81 in total

Review 1.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

3.  In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.

Authors:  Bram M W Diederen; Inge van Duijn; Piet Willemse; Jan A J W Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

4.  Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.

Authors:  Brian T Tsuji; Michael J Rybak; Kerry L Lau; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

5.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

6.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

7.  In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Authors:  Amira A Bhalodi; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 8.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Study on daptomycin use and implementation of an antimicrobial stewardship program.

Authors:  Camille Castel; Arnaud de La Blanchardière; Jocelyn Michon; Vincent Cattoir; Guillaume Saint-Lorant
Journal:  Int J Clin Pharm       Date:  2016-03-07

10.  Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients.

Authors:  Nagendra N Mishra; Arnold S Bayer; Pamela A Moise; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2012-08-16       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.